Venus Medtech, a Chinese company that produces heart valve replacement devices, plans to raise up to $381 million in an initial public offering (IPO) in Hong Kong next month against headwinds including civil unrest in the Asian financial hub for nearly six months.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
